Medtronic (MDT) Stock Moves -1.05%: What You Should Know

Medtronic (MDT) ended the recent trading session at $89.29, demonstrating a -1.05% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a loss of 1.6% for the day. Meanwhile, the Dow experienced a drop of 1.23%, and the technology-dominated Nasdaq saw a decrease of 2.24%. Heading into today, shares of the medical device company had gained 2.09% over the past month, outpacing the Medical sector's loss of 3.44% and lagging the S&P 500's gain of 2.25%.The investment community will be paying close attention to the earnings performance of Medtronic in its upcoming release. The company is slated to reveal its earnings on August 19, 2025. The company is forecasted to report an EPS of $1.23, showcasing no movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $8.37 billion, up 5.73% from the prior-year quarter. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $5.55 per share and a revenue of $35.29 billion, representing changes of +1.09% and +5.22%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for Medtronic. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.01% lower within the past month. Right now, Medtronic possesses a Zacks Rank of #4 (Sell). Looking at its valuation, Medtronic is holding a Forward P/E ratio of 16.27. Its industry sports an average Forward P/E of 17.39, so one might conclude that Medtronic is trading at a discount comparatively. Investors should also note that MDT has a PEG ratio of 2.34 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical - Products industry stood at 2.14 at the close of the market yesterday. The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 183, which puts it in the bottom 26% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks